5 news items
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
ARGX
9 May 24
to determine dose response ahead of Phase 3 study startPhase 1b/2a trials of ARGX-119 to assess early signal
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ARGX
16 Apr 24
of rapid onset and maintenance of clinical response: In the open-label Stage A of the ADHERE study, 67% of patients treated with VYVGART Hytrulo
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
ARGX
27 Mar 24
datapoints were gathered including the clinESSDAI, STAR (Sjogren's Tool for Assessing Response), biomarker data, and the change in lymphocytic infiltrate
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
ARGX
26 Mar 24
a sustained platelet count response compared to placebo. VYVGART demonstrated rapid onset of effect in chronic and persistent ITP patients, as well as a 51
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
ARGX
7 Mar 24
) antibody positive and in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive
- Prev
- 1
- Next